CONGRESS | #ASH23 | iman aboudalle American University of Beirut reports the impact of DNMT3A mutation on post-transplant outcomes in pts with AML patients receiving allo-HCT in first remission using #EBMT database. N=1374, DNMT3A mutant=46%. DNMT3A mutation negatively affects post-transplant…

Outstanding talk by the myeloid malignancy Lebanese 🇱🇧 superstar Dr iman aboudalle at #ASH23 #ASH2023

Looking forward to a great meeting #EHA23 🤩🤩

Straight from #EHA2022 !
Congratulations Ali Taher for Education & mentoring award ! What an inspiring speech! Very well deserved 🇱🇧

برنامج
'The Researcher '
على الـLBCI...
أبحاث رائدة من أجل مجتمع أفضل
bit.ly/3gqqOqE
#LBCILebanon #LBCINews

The Researcher الجمعة ⚠️⚠️ 22:10 مساء على ال LBCI youtu.be/hP7OYIrUy2o via YouTube Do not miss this episode tomorrow American University of Beirut LBCI Lebanon English LBCI TV American University of Beirut Medical Center #NKBCI #theresearcher

What an amazing group of bright minds to have lunch with in#ASH21

👍🏻Initial results of AZA-VEN-Gilt in FLT3m AML presented by Nicholas Short MD at #ASH21 . Very encouraging 🤩 ORR=100% - MRDneg=86% - 6-mo OS=92% in frontline tx

#ASHKudos to our rising stars 🌟 from American University of Beirut Medical Center chairing a very important session at #ASH21 discussing CART therapy in T cell lymphomas. #lymsm 👏🏻👏🏻Razan Mohty Abdul-Hamid Bazarbachi, MD 🥳🥳

Three #leukemia fellow generations reunited at #ASH21 with the amazing doctor Ferrajoli 🧡🧡 Naveen Pemmaraju, MD Talha Badar MD Anderson Cancer Center

✅ Another monoclonal antibodies in combinations with AZA-VEN 💡Magrolimab and IMGN632 in AML.. Looking forward for phase 3 trials showing ⬆️OS Naval Daver, M.D. #ASH21

🟢 Moving forward beyond AZA-VEN in AML with triple combinations. Cuzatuzumab, anti-CD70 antibody looks safe and promising 👍🏻👍🏻

Look at these straight curves for favorable AML treated with Cladribine/LDAC-VEN alt AZA-VEN regimen in older patients 😍 I think we able to cure them 🎉 Tapan Kadia Hagop Kantarjian,MD

Best part of #ASH21 is to reconnect after 2 years 🥰🥰 So happy to see you both Tapan Kadia Ghayas Issa

Small study with only 9 patients, but exciting results with ORR 100% and 6-month OS of 100% using all oral treatment with oral Decitabine and venetoclax in high risk #MDS #ASH21 Sangeetha Venugopal MD,MS G Garcia-Manero

Sabatolimab added to AZA in #MDS appears to induce longer response duration ORR=57% with mDOR of 17 mo. ‼️More impressive is mDOR of 21 mo in TP53 mutant MDS. #ASH21